PLK1 and acute lymphoblastic leukemia: Most T-ALL cell lines assessed demonstrated heightened sensitivity (EC50 below 100 nM) to the PLK1 inhibitor volasertib, except for TALL-1, which exhibited a poor response (Fig. 3G, H).